Cellectis (CLLS) Cash from Investing Activities (2015 - 2026)
Cellectis' (CLLS) quarterly Cash from Investing Activities came in at -$6.2 million in Q1 2026, down 245.99% year-on-year from $4.2 million in Q1 2025, and down 127.46% quarter-over-quarter from $22.5 million in Q4 2025.
Cellectis (CLLS) Cash from Investing Activities (2015 - 2026) Analysis & Trends
Cellectis' Cash from Investing Activities history runs 12 years deep, the most recent figure standing at -$6.2 million for Q1 2026.
- On a quarterly basis, Cash from Investing Activities fell 245.99% year-over-year to -$6.2 million in Q1 2026; TTM through Mar 2026 was -$39.9 million, a 58.7% increase from a year earlier, with the FY2025 full-year figure at -$29.5 million, up 71.32% from the prior year.
- Cash from Investing Activities eased to -$6.2 million in Q1 2026 per CLLS's latest filing, from $22.5 million in the prior quarter.
- Across five years, Cash from Investing Activities topped out at $22.5 million in Q4 2025 and bottomed at -$106.4 million in Q2 2024.
- The 5-year median for Cash from Investing Activities is -$1.1 million (2022), against an average of -$9.2 million.
- Biggest YoY gain for Cash from Investing Activities was 7544.33% in 2024; the steepest drop was 5916.34% in 2024.
- Year by year, Cash from Investing Activities stood at -$730000.0 in 2022, then plunged by 1770.27% to -$13.7 million in 2023, then decreased by 22.03% to -$16.7 million in 2024, then soared by 234.75% to $22.5 million in 2025, then slumped by 127.46% to -$6.2 million in 2026.
- Per Business Quant, the three latest CLLS Cash from Investing Activities figures stand at -$6.2 million (Q1 2026), $22.5 million (Q4 2025), and -$3.4 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,741.39 Bn | 66,741.11 Bn | - | - |
| 2 | Nanobiotix | 1,912.31 Bn | 1,912.25 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 467.15 Bn | 462.36 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 123.00 Bn | 115.76 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 70.22 Bn | 61.47 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 62.93 Bn | 62.93 Bn | - | - |
| 8 | Argenx Se | 55.76 Bn | 50.57 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.70 Bn | 34.69 Bn | 959.66 Mn | -25.54 Mn |
| 10 | Cellectis | 290.61 Mn | 104.95 Mn | - | -6.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.17 Mn |
| Mar 31, 2026 | -6.17 Mn |
| Dec 31, 2025 | 22.45 Mn |
| Dec 31, 2025 | 22.45 Mn |
| Sep 30, 2025 | -3.44 Mn |
| Sep 30, 2025 | -3.44 Mn |
| Jun 30, 2025 | -52.72 Mn |
| Jun 30, 2025 | -52.72 Mn |
| Mar 31, 2025 | 4.22 Mn |
| Mar 31, 2025 | 4.22 Mn |
| Dec 31, 2024 | -16.66 Mn |
| Dec 31, 2024 | -16.66 Mn |
| Sep 30, 2024 | 22.33 Mn |
| Sep 30, 2024 | 22.33 Mn |
| Jun 30, 2024 | -106.43 Mn |
| Jun 30, 2024 | -106.43 Mn |
| Mar 31, 2024 | -2.05 Mn |
| Mar 31, 2024 | -2.05 Mn |
| Dec 31, 2023 | -13.65 Mn |
| Dec 31, 2023 | -13.65 Mn |